At 10.3% CAGR, the Middle East & Africa stem cell therapy market is projected to be worth US$ 96.12 million by 2028, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa stem cell therapy market was valued at US$ 53.25 million in 2022 and is expected to reach US$ 96.12 million by 2028, registering a CAGR of 10.3% from 2022 to 2028. Use of induced pluripotent stem cells in regenerative medicines and research activities and product innovations are the critical factors attributed to the Middle East & Africa stem cell therapy market expansion.

Per the Frontiers Media S.A. 2023 report, progress in the field of induced pluripotent stem cells (iPSCs) has opened a new gateway for research in therapeutics. iPSCs are mainly intended for research and clinical studies such as disease modeling, regenerative medicine, and drug discovery/drug cytotoxicity studies. For example, iPSCs can be used to convert differentiated somatic cells to multipotent stem cells to generate different cell types of adult tissues. Thus, iPSCs have shown promising results in regenerative medicine, particularly for replacing diseased or injured cells. iPSCs are widely used to regenerate tissue-specific cells for transplantation in patients for treating injuries and degenerative diseases. Studies such as drug discovery involving screening of small molecules and toxicity testing for safety assessment have been successfully disclosed positive iPSCs-based results. The aforementioned factors are expected to offer lucrative growth opportunities to companies in the Middle East & Africa stem cell therapy market in the coming years.

On the contrary, high cost of approved treatments hurdles the growth of Middle East & Africa stem cell therapy market.

Based on type, the Middle East & Africa stem cell therapy is segmented into adult stem cell therapy, embryonic stem cell therapy, induced pluripotent stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held 60.0% share of Middle East & Africa stem cell therapy market in 2022, amassing US$ 31.95 million. It is projected to garner US$ 58.82 million by 2028 to expand at 10.7% CAGR during 2022–2028. The adult stem cell therapy segments is further segmented into hematopoietic stem cell therapy, umbilical cord stem cell therapy, neuronal stem cell therapy, and mesenchymal stem cell.

Based on treatment, the Middle East & Africa stem cell therapy is bifurcated into allogeneic and autologous. The allogeneic segment held 55.9% share of Middle East & Africa stem cell therapy market in 2022, amassing US$ 29.79 million. It is projected to garner US$ 53.03 million by 2028 to expand at 10.1% CAGR during 2022–2028.

Based on application, the Middle East & Africa stem cell therapy is segmented into musculoskeletal, dermatology, cardiology, drug discovery & development, and other applications. The musculoskeletal segment held 33.2% share of Middle East & Africa stem cell therapy market in 2022, amassing US$ 17.66 million. It is projected to garner US$ 31.46 million by 2028 to expand at 10.1% CAGR during 2022–2028.

Based on end user, the Middle East & Africa stem cell therapy is bifurcated into hospitals & specialty clinics and academic & research institutes. The academic & research institutes segment held 53.5% share of Middle East & Africa stem cell therapy market in 2022, amassing US$ 28.51 million. It is projected to garner US$ 52.16 million by 2028 to expand at 10.6% CAGR during 2022–2028.

Based on country, the Middle East & Africa stem cell therapy is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Our regional analysis states that the UAE captured 43.4% share of Middle East & Africa stem cell therapy market in 2022. It was assessed at US$ 23.09 million in 2022 and is likely to hit US$ 42.98 million by 2028, exhibiting a CAGR of 10.9% CAGR during 2022–2028.  

Key players profiled in the Middle East & Africa stem cell therapy market report Lonza Group AG, Pluri Inc, Smith & Nephew Plc, and TiGenix NV (Takeda Pharmaceutical Company Limited), among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com